Recent Quotes (30 days)

You have no recent quotes
chg | %

Transition Therapeutics Inc  

(Public, TSE:TTH)   Watch this stock  
Find more results for TTH
0.00 (0.00%)
Delayed:   3:34PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 4.80 - 9.47
Open     -
Vol / Avg. 0.00/866.00
Mkt cap 304.03M
P/E     -
Div/yield     -
EPS -1.55
Shares 35.32M
Beta -0.05
Inst. own     -
May 6, 2015
Q3 2015 Transition Therapeutics Inc Earnings Release (Estimated) Add to calendar
Mar 2, 2015
Transition Therapeutics Inc at Cowen Health Care Conference
Feb 9, 2015
Q2 2015 Transition Therapeutics Inc Earnings Call
Feb 9, 2015
Q2 2015 Transition Therapeutics Inc Earnings Release

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -148.26% -40.82%
Return on average equity -187.48% -47.22%
Employees 24 -
CDP Score - -


101 College St Suite 220
+1-416-2607770 (Phone)
+1-416-2602886 (Fax)

Website links


Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing therapeutics for disease indications with markets. The Company�s wholly-owned subsidiary, Transition Therapeutics Ireland Limited is developing CNS drug candidate ELND005 for the treatment of Alzheimer�s disease and Down syndrome. The Company�s technologies in development include ELND005 for the treatment of Alzheimer�s disease, bipolar disorder and Down syndrome, and TT401/402 for the treatment of diabetes. The Company is engaged in developing disease-modifying small molecule therapeutics that act by preventing the formation of and breaking down amyloid beta peptide aggregates. TT-401 provides glycemic control and other effects, including weight loss.

Officers and directors

Tony F. Cruz Ph.D. Chairman of the Board, Chief Executive Officer
Nicole Rusaw Chief Financial Officer
Age: 39
Carl Damiani Chief Operating Officer, Vice President - Business Development
Age: 39
Bruce Connop Vice President - Non-Clinical & Pharmaceutical Development
Age: 43
Aleksandra Pastrak Vice President - Clinical Development and Medical Officer
Age: 46
Louis Alexopoulos Secretary
Michael Richard Dwyer Ashton Lead Independent Director
Age: 68
Paul Baehr Independent Director
Age: 69
Christopher M. Henley Independent Director
Age: 52
Gary W. Pace Ph.D. Independent Director
Age: 66